In a phase 3 trial, adjuvant durvalumab did not significantly improve disease-free survival in early-stage non-small cell lung cancer following resection compared to placebo. The study included over 1,200 patients with no EGFR or ALK mutations, and results were presented at the European Society for Medical Oncology Congress. The findings contrast with prior trials showing benefits with adjuvant atezolizumab and pembrolizumab in a similar patient population. Despite the negative results, the need for predictive biomarkers in this setting was emphasized, and ongoing research is exploring new treatment options, including vaccines. Clinical implications and future directions remain uncertain.
Source link
No DFS Benefit With Adjuvant Durvalumab in Early NSCLC
